The U.S. Supreme Court has delivered a decisive victory to glyphosate manufacturers by determining that federal safety determinations preempt state-level lawsuits claiming inadequate product warnings. In a 7-2 decision issued on June 25, 2026, the Court ruled that the Environmental Protection Agency’s finding that glyphosate is safe when used properly bars consumers from suing under state failure-to-warn theories. Justice Brett Kavanaugh wrote the majority opinion, establishing that the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA) prevents individual states from imposing labeling requirements that differ from federal standards.
This ruling effectively reverses a 2019 Missouri jury verdict that had awarded John Durnell, an individual plaintiff, more than $1 million for a cancer claim related to Roundup, the herbicide product at the center of the case. The decision stands as one of the most consequential mass tort rulings in recent years, immediately impacting hundreds of thousands of pending cases. With approximately 200,000 Roundup-related lawsuits currently against Bayer pending in the courts, the ruling is expected to block or significantly weaken claims from home users who allege they were not adequately warned about potential cancer risks. Bayer, which acquired Monsanto (Roundup’s manufacturer) in 2018, had previously set aside $16 billion to settle cases and had proposed a $7.25 billion class-action settlement earlier in 2026. The Supreme Court’s intervention now substantially reduces the financial exposure Bayer faces from remaining litigation.
Table of Contents
- How Did the Supreme Court Limit Glyphosate Lawsuits?
- The Original Case That Changed Everything for Glyphosate Litigation
- What Happens to the 200,000 Pending Roundup Lawsuits?
- How Does Federal Preemption Work in Product Liability Cases?
- What Did the EPA Actually Determine About Glyphosate Safety?
- Bayer’s Financial Exposure and Settlement Negotiations
- The Dissent and the Path for Future Regulatory Challenges
How Did the Supreme Court Limit Glyphosate Lawsuits?
The Court’s ruling rests on a doctrine called federal preemption, which holds that when federal agencies set safety standards, states cannot impose conflicting requirements that effectively contradict those standards. FIFRA grants the EPA authority to determine whether pesticides are safe and what warnings must appear on labels. Because the EPA has determined that glyphosate is safe when used according to directions and has not required a cancer warning label, the Court concluded that state courts cannot allow juries to second-guess that determination through product liability lawsuits. This reasoning differs from many other product liability cases, where states traditionally retained broad power to set safety standards for products sold within their borders.
Justice Kavanaugh’s opinion emphasized that allowing individual states to impose their own labeling requirements would undermine the uniform federal system that FIFRA established. If California or Missouri could require warnings that the federal government does not mandate, manufacturers would face a patchwork of conflicting state requirements. This, the majority reasoned, would frustrate the EPA’s regulatory scheme and effectively give states a veto over federal safety determinations. The two dissenting justices, led by Justice Ketanji Brown Jackson, argued that the ruling strips consumers of a traditional remedy for inadequate warnings and that FIFRA’s text does not clearly preempt state tort claims.
The Original Case That Changed Everything for Glyphosate Litigation
John Durnell’s case began as a straightforward failure-to-warn lawsuit in Missouri state court. In 2019, a jury found that Roundup was dangerous and that Monsanto had failed to adequately disclose cancer risks, awarding Durnell $1 million in damages. That verdict became a template for thousands of similar cases nationwide, as attorneys established that juries would compensate glyphosate users who developed cancer. The case gained momentum when multiple lawsuits and settlements followed, with some verdicts exceeding $100 million.
However, those earlier cases were won under state tort law, before the question of federal preemption reached the Supreme Court. The Supreme Court’s decision to reverse Durnell’s verdict and establish that EPA safety findings preempt state lawsuits has reshaped the entire legal landscape. Plaintiffs who could once rely on state juries to award damages for allegedly inadequate warnings now face an insurmountable federal bar. This shift means that even if a jury believes glyphosate caused harm, the jury cannot award damages based on a failure-to-warn theory because the EPA has already determined that the product is safe. The ruling does not prevent injured parties from pursuing other theories of liability, such as design defects, but it eliminates one of the most powerful tools plaintiffs have used in mass tort litigation.
What Happens to the 200,000 Pending Roundup Lawsuits?
Approximately 200,000 Roundup-related claims against Bayer remain pending in federal and state courts as of mid-2026. The supreme court‘s decision will almost certainly trigger a wave of dismissals of cases based purely on failure-to-warn allegations. Many of these lawsuits have not yet reached trial, meaning they existed in a legal limbo awaiting clarification of the preemption question. Defense attorneys for Bayer have already begun filing motions to dismiss based on the new precedent, arguing that plaintiffs have no valid legal claim under state law if the EPA has determined the product is safe.
However, the practical impact may be more complicated than a simple numerical reduction. Some plaintiffs’ attorneys may attempt to restructure their cases around other legal theories, such as negligence in manufacturing, fraud in suppressing scientific studies, or misrepresentation. Others may pursue state law claims that do not rely on warnings, though those will face higher evidentiary burdens. The ruling does not make pending cases disappear; it changes which cases have viable legal theories. For plaintiffs who had counted on a 2019-style jury verdict, the Supreme Court decision represents a fundamental change in their chances of recovery.
How Does Federal Preemption Work in Product Liability Cases?
Federal preemption doctrine exists in a tension with traditional state authority over consumer protection and product safety. In many product liability areas, states retain broad discretion to establish warnings and safety standards beyond federal minimums. For example, state courts can impose requirements on automobile manufacturers even when the National Highway Traffic Safety Administration has set federal standards. However, the Supreme Court has carved out exceptions for regulated industries where Congress explicitly gave a federal agency comprehensive authority. FIFRA is one of those statutes, and the Court determined that pesticide labeling falls squarely within the EPA’s exclusive domain.
The practical consequence is that different industries face different preemption rules. A pharmaceutical company suing under federal preemption can often succeed because the FDA has explicit statutory authority to approve drug labels. A pesticide manufacturer now has a similar advantage under FIFRA. However, a manufacturer of household appliances or furniture typically cannot invoke preemption as a defense because no federal agency has been given comparable regulatory authority. Plaintiffs’ lawyers have been forced to recalibrate their strategies nationwide. In jurisdictions that have been friendlier to plaintiffs, such as California and Illinois, the ruling limits what state juries can do, even though those states’ legislatures might theoretically prefer stronger consumer protection than the federal standard.
What Did the EPA Actually Determine About Glyphosate Safety?
The EPA has repeatedly reviewed glyphosate and concluded that it is not a carcinogen when used according to label directions. This determination has remained consistent through multiple administrations of both political parties, though it has generated significant controversy within the scientific community. The EPA’s position differs from the International Agency for Research on Cancer (IARC), a World Health Organization body that classified glyphosate as “probably carcinogenic to humans” in 2015. This scientific disagreement between U.S. and international regulatory bodies has fueled public concern and litigation.
A critical limitation of the Supreme Court’s ruling is that it locks consumers into the EPA’s determination, regardless of subsequent scientific developments. If new evidence emerges suggesting health risks that the EPA had not previously considered, or if the EPA’s review process is later found to have been flawed, the ruling does not provide a mechanism for states to protect their citizens through the court system. Plaintiffs in other countries, notably in Europe, have pursued regulatory pathways that have resulted in restrictions on glyphosate use. The Supreme Court’s decision means American consumers no longer have the option of seeking a jury verdict based on state tort law, even if they believe the EPA’s decision was wrong. This represents a significant shift in the balance between administrative expertise and jury democracy.
Bayer’s Financial Exposure and Settlement Negotiations
Bayer had reserved $16 billion to settle Roundup-related claims as of 2026, a figure that reflected the manufacturer’s exposure under the previous legal regime where failure-to-warn lawsuits remained viable. The company also proposed a $7.25 billion class-action settlement earlier in 2026, which would have resolved large numbers of claims at once. The Supreme Court ruling dramatically improves Bayer’s financial position by eliminating the legal basis for the majority of these claims.
Remaining settlements are likely to be smaller and focused on plaintiffs who can pursue alternative theories of liability or who wish to settle to avoid the uncertainty of litigation. The ruling may also affect insurance coverage disputes between Bayer and its insurers. Some insurance policies contain carve-outs for federal preemption issues or changes in law, meaning that insurers could argue they are not required to cover claims that are now preempted. These disputes will likely generate additional litigation between Bayer and its carriers, even as the core product liability exposure shrinks.
The Dissent and the Path for Future Regulatory Challenges
Justice Ketanji Brown Jackson’s dissent in the case emphasized that FIFRA’s text does not explicitly preempt state tort claims and that the majority was creating a new preemption doctrine without clear statutory support. She argued that consumers should retain access to courts when they believe they have been harmed, particularly when scientific evidence continues to support the possibility of risk. The dissent signals that future cases may attempt to narrow the scope of FIFRA preemption, perhaps by distinguishing cases involving newer scientific evidence or regulatory failings.
The ruling also reflects the Court’s current doctrinal stance on preemption, which has shifted in a direction favorable to federal authority over state power in regulated industries. This shift has implications beyond glyphosate, potentially affecting future litigation over pharmaceuticals, medical devices, and other heavily regulated products. As regulatory agencies face mounting pressure from environmental and health advocates to reconsider their positions on various chemicals and pesticides, the question of whether agencies can be held accountable through litigation—as opposed to administrative appeals—will continue to generate controversy.